SecBot SecBot
SECBOTREPLAY Home › Report › BMRN

BMRN · BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, driven…

BIOMARIN PHARMACEUTICAL INC · 8-K filed Nov 2, 2026 at 16:07 ET

At the news

BEARISHIMPACT 6/10

8-K filed Nov 2, 2026 at 16:07 ET

BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, driven by the Amicus acquisition (GALAFOLD and POMBILITI+OPFOLDA) and 12% VOXZOGO growth. GAAP EPS was -$0.63 (vs consensus -$0.11), heavily impacted by $288M in acquired IPR&D charges and $99M in intangible amortization. Non-GAAP EPS was $0.23. Full-year 2026 revenue guidance was lowered to $3.80B-$3.90B (from $3.875B-$3.925B) due to order timing uncertainty, and Non-GAAP EPS guidance was slashed to $2.80-$3.10 (from $4.90-$5.10) reflecting the Alesta acquisition and BMN 450 license charges.

  • Q3 2026 total revenues $1.025B, +32% YoY (from $776M)
  • GAAP net loss -$123M vs -$31M YoY; GAAP diluted EPS -$0.63 vs -$0.16 YoY
  • Non-GAAP income $45M vs $22M YoY; Non-GAAP diluted EPS $0.23 vs $0.12 YoY
  • Full-year 2026 revenue guidance lowered to $3.80B-$3.90B (from $3.875B-$3.925B)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access